Stock fact sheet · data as of
Varex Imaging Corporation (VREX): fair value, margin of safety and Wheel Score
Healthcare · Medical - Devices · United States · Blend
Is VREX undervalued?
VREX closed at 18.39 on 16 Oct 2026, more than 30% above the GLS average fair value of 11.87. Only 1 of the 6 models that produced a value sit above the price. By our models the shares are priced well beyond what the filed earnings, cash flow and book value support; the Sunday Scan drops names like this at the "below fair value" rule.
There is a wide gap between GLS Growth (0.7564) and Graham Growth (30.03). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files VREX under Blend.
Nine valuation models for VREX
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 9.70 | -47% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 11.80 | -36% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 30.03 | +63% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 13.12 | -29% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 0.7564 | -96% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 5.83 | -68% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 0.4945 | -97% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 14.50 | -21% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Varex Imaging Corporation scores 6 of 9 on the Piotroski F-score: a middling result that passes the Sunday Scan's "6 or more" rule. Some of the nine tests on profitability, leverage and efficiency are failed, so the accounts are worth a look before selling a put on the name. A GLS Moat score of 2.0/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -8.0%, ROE -14.9%, ROA -6.3% - with debt at 0.85 times equity and negative free cash flow.
Varex Imaging Corporation pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Medical 64%, Industrial 36% (quarter Q3 FY2026).
Institutional ownership scores 10/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales; the last recorded insider buy was on 11 Sep 2026.
| Piotroski F-score | 6 / 9 | ROIC | -8.0% |
|---|---|---|---|
| GLS Moat | 2.0 / 10 | ROE | -14.9% |
| Debt / equity | 0.85 | ROA | -6.3% |
| Free-cash-flow yield | -2.6% | Payout ratio | 0% |
| Institutions | 10 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 50: Fair
A Wheel Score of 50 puts Varex Imaging Corporation in the Fair band - below the 70 the Sunday Scan requires. Value 0/25, Health 13/20, Moat 3/15, Premium 20/20 and Stability 13/20; the weakest part is Value (0/25).
Implied volatility is 57% on the near-the-money contracts 20-60 days out - inside the 35-60% range the Wheel Score pays full marks for: enough premium to be worth selling, not so much that the risk is unpaid. Chain open interest is thin - 652 contracts across every expiry - so fills at a fair price are not guaranteed; a 30-45-day put may not exist at a usable strike.
Volume runs at 870k shares a day on a market cap of $781M, with a beta of 0.97; the Stability part of the Wheel Score gives that 13 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 0 / 25 | -55% margin of safety | |
| Health | 13 / 20 | Piotroski 6/9 | |
| Moat | 3 / 15 | moat 2.0/10 | |
| Premium | 20 / 20 | implied volatility 57% | |
| Stability | 13 / 20 | 870k shares/day, $781M cap, beta 0.97 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 17 Nov 2026 (after the close), 32 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Devices
The 12 companies below are the closest to Varex Imaging Corporation by market cap within the Medical - Devices industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| BBNX Beta Bionics, Inc. | 17.31 | - | - | 42Weak | $779M |
| INMD InMode Ltd. | 14.32 | 20.58 | +30% | 72Good | $824M |
| CTKB Cytek Biosciences, Inc. | 5.41 | 2.54 | -113% | 42Weak | $703M |
| AHCO AdaptHealth Corp. | 6.39 | 34.79 | +82% | 45Weak | $871M |
| SIBN SI-BONE, Inc. | 19.47 | 36.89 | +47% | 45Weak | $873M |
| BVS Bioventus Inc. | 13.81 | 26.25 | +47% | 73Good | $943M |
| AVR Anteris Technologies Global Corp. | 6.36 | - | - | 45Weak | $620M |
| PACB Pacific Biosciences of California, Inc. | 1.99 | - | - | 38Weak | $619M |
| PRCT PROCEPT BioRobotics Corporation | 17.51 | 44.96 | +61% | 45Weak | $997M |
| KIDS OrthoPediatrics Corp. | 22.57 | 1.14 | -1883% | 44Weak | $589M |
| LMRI Lumexa Imaging Holdings, Inc. Common Stock | 10.78 | 7.46 | -45% | 30No options | $1.0B |
| IART Integra LifeSciences Holdings Corporation | 13.53 | 11.25 | -20% | 45Weak | $1.1B |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about VREX
Is VREX undervalued right now?
No: at 18.39 the stock trades 55% above the GLS average fair value of 11.87 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of VREX and what does it mean?
VREX scores 50 out of 100 (Fair). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for VREX?
11.87 per share as of 16 Oct 2026 - the simple average of the 6 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Varex Imaging Corporation report earnings next?
The next earnings report is due on 17 Nov 2026 (after the close), 32 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does VREX have listed options, and how liquid are they?
Yes. The nightly snapshot found 110 listed contracts with 652 open interest across all expiries and implied volatility of 57% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.